Ask about this productRelated genes to: PSMA5 antibody
- Gene:
- PSMA5 NIH gene
- Name:
- proteasome subunit alpha 5
- Previous symbol:
- -
- Synonyms:
- ZETA
- Chromosome:
- 1p13.3
- Locus Type:
- gene with protein product
- Date approved:
- 1995-05-03
- Date modifiied:
- 2016-10-05
Related products to: PSMA5 antibody
Related articles to: PSMA5 antibody
- Inositol is a natural carbocyclic sugar that plays an essential role in regulating the vital cellular functions of plants and animals. Existing research has explored methyl derivatives of inositol, reporting on their various biological activities, including antitumor, anti-inflammatory, and anti-osteoporosis activities. Our previous study demonstrated that L-quebrachitol, a methyl derivative of inositol, enhances osteoblastogenesis and bone formation; however, its effect on osteoclastogenesis remains unclear. Consequently, we aimed to investigate the effect of L-quebrachitol on receptor activator of nuclear factor-κB ligand-induced osteoclastogenesis in pre-osteoclastic RAW 264.7 cells, and bone resorption in an ovariectomized rat model. The results revealed that L-quebrachitol suppressed RANK-mediated signaling, including nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) and Fos proto-oncogene (cFOS) pathways, at both the gene and protein levels. Moreover, the critical transcription factor for osteoclastogenesis, nuclear factor of activated T cells c1 (NFATc1), was downregulated. Inhibition of osteoclast-associated marker genes encoding proteolytic enzymes, such as tartrate-resistant acid phosphatase (TRAP), matrix metallopeptidase 9 (MMP-9), and cathepsin K, led to reduced formation of TRAP-positive multinucleated cells and resorption pits. In addition, proteasome subunit alpha type-5 (PSMA5), which is involved in the degradation of the NF-κB inhibitor, was also suppressed. In particular, the animal study clearly supported the bone homeostasis property of the agent by increasing the BV/TV (bone volume/total volume) and Tb.Th (trabecular thickness) in ovariectomized rats. These findings demonstrate the dose-dependent inhibitory effect of L-quebrachitol on osteoclastogenesis through the modulation of RANK-mediated signaling pathways and prevention of bone loss in an animal model. However, further exploration of the potential of L-quebrachitol as an effective approach for osteoporosis is required. - Source: PubMed
Publication date: 2026/01/20
Rattajak PurithatAroonkesorn ArateeYodthong ThanintornIssuriya AcharapornMaskaew SirilukSmythe CarlWititsuwannakul RapepunPitakpornpreecha Thanawat - [At]PSMA-5 is a novel α-emitting therapeutic agent designed to target prostate-specific membrane antigen (PSMA), which is overexpressed in metastatic castration-resistant prostate cancer (mCRPC). Unlike β-emitting radioligands, [At]PSMA-5 delivers highly localized cytotoxicity while minimizing damage to surrounding normal tissues. To enable clinical application, the objective of this study is to scale up the lab-scale synthesis to an automated manufacturing process that ensures high reproducibility and sufficient radioactivity for human administration. - Source: PubMed
Publication date: 2025/12/27
Naka SadahiroWatabe TadashiShirakami YoshifumiOoe KazuhiroKurimoto KentaSakai ToshihiroToyoshima AtsushiMurakami MasashiKon YukiyoshiHaba HiromitsuCardinale JensGiesel Frederik LIsohashi KayakoTomiyama Noriyuki - Antidepressant-induced mania (AIM) is a significant clinical concern, primarily studied in bipolar disorder patients. Limited research exists on AIM in unipolar depression, with reported incidence rates of 3.0-8.2 %. - Source: PubMed
Publication date: 2025/11/16
Huang Shiau-ShianChao Ying-TingChen Yu-NingSu Mei-HsinChang Chiao-ErhTsai Shih-JenKuo Po-Hsiu - Astatine (At) is an alpha-emitting nuclide with a 7.2-hour half-life that can be produced using a 30-MeV cyclotron. In recent years, the number of production sites worldwide has been increasing, attracting growing attention to At. We have developed a novel At-labeled PSMA-targeted agent ([At]PSMA-5). After conducting preclinical evaluations of its antitumor efficacy and safety, we initiated a first-in-human, investigator-initiated clinical trial in patients with metastatic castration-resistant prostate cancer. To date, the drug has been administered to a total of nine patients, and we have reported high accumulation of [At]PSMA-5 in recurrent and metastatic lesions. While further efforts are required for the social implementation of At-based targeted alpha therapy, including the establishment of a supply chain and the accumulation of additional clinical evidence, PSMA-targeted alpha therapy using At represents a promising treatment modality owing to its cyclotron-based production, sustainability, and clean decay characteristics. - Source: PubMed
Publication date: 2025/09/30
Watabe TadashiNaka SadahiroShirakami YoshifumiKaneda KazukoMurakami MasashiToyoshima AtsushiCardinale JensGiesel Frederik L - We aimed to develop a predictive model integrating G2M-related genes to enhance the prognostication of colon cancer. - Source: PubMed
Publication date: 2025/08/10
Song XinDou YanShen Xiaoyong